EHS
EHS

iDose shows promising results for glaucoma in phase 2 trial


October 02, 2022

2 min watch

Source:

Sarkisian SR. iDose. Presented at: American Academy of Ophthalmology meeting; Sept. 30-Oct. 3, 2022; Chicago.

Disclosures:
Sarkisian reports being an investigator in the iDose study and consulting for Glaukos.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — In this Healio Video Perspective from the AAO meeting, Steven R. Sarkisian, MD, discusses data from a phase 2 trial investigating the iDose sustained-release travoprost implant from Glaukos for the treatment of glaucoma.

“What’s really cool is that we finally have something that can get patients off medicine and that has some endurance and longevity, without all the topical side effects,” Sarkisian said.



Source link

EHS
Back to top button